Monographie - Linezolid

Pēdējā atjaunošana :
19/11/2024

Linezolid

Ķīmiskā uzbūve

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Bogadril	Dienvidāfrikas Republika, Meksika
Entavar	Indija
Linezolid	Argentīna, Ekvadora, Kanāda, Peru, Rumānija, Spānija, Šveice, Vācija
Linezolida	Čīle
Linezolide	Šveice
Linezone	Turcija
Linsyn	Peru
Litasina	Čīle, Peru
Litrecan	Argentīna, Čīle, Peru
Milbrar	Meksika
Nodizil	Turcija
Pneumolid	Rumānija
Renyvozon	Meksika
Tymbro	Peru
Voxazoldin	Ēģipte
Xolid	Indija
Zizolid	Turcija
Zyvox	Amerikas Savienotās Valstis, Argentīna, Austrālija, Čīle, Ēģipte, Īrija, Jaunzēlande, Lielbritānija, Malaizija, Ungārija
Zyvoxam	Kanāda, Meksika
Zyvoxid	Austrija, Beļģija, Dānija, Ekvadora, Francija, Holande, Islande, Itālija, Kolumbija, Norvēģija, Polija, Portugāle, Rumānija, Somija, Spānija, Šveice, Turcija, Ungārija, Vācija, Venecuēla, Zviedrija

Literatūras saraksts : Linezolid

	tips	publicēšana
1607	Žurnāls	Trissel LA, Zhang Y, Xu QA. Incompatibility of erythromycin lactobionate and sulfamethoxazole/trimethoprim with linezolid injection. Hosp Pharm 2000 ; 35: 1192-1196.
1658	Žurnāls	Zhang Y, Xu QA, Trissel LA, Willimas KY. Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium. J Am Pharm Assoc 2000 ; 40: 520-524.
1659	Žurnāls	Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics. J Am Pharm Assoc 2000 ; 40: 509-514.
1668	Žurnāls	Zhang Y, Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three quinolone antibiotics. Ann Pharmacotherapy 2000 ; 34: 996-1001.
1712	Žurnāls	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1803	Žurnāls	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Žurnāls	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	Žurnāls	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Žurnāls	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2057	Žurnāls	Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003 ; 51: 849-855.
2163	Žurnāls	Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA. Linezolid stability in peritoneal dialysis solutions. Perit Dial Int 2002 ; 22: 419-422.
2233	Žurnāls	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Žurnāls	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Žurnāls	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2353	Žurnāls	Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y. Compatibility and stability of linezolid injection admixted with gentamicin sulfate and tobramycin sulfate. Int J Pharm Compound 2000 ; 4, 6: 476-479.
3122	Žurnāls	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3560	Laboratorija	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3824	Žurnāls	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3828	plakāts	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakāts	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Žurnāls	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3997	Žurnāls	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	Žurnāls	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4117	Žurnāls	Taylor R, Sunderland B, Luna G, Czarniak P. Evaluation of the stability of linezolid in aqueous solution and commonly used intravnous fluids. Drug Design Dev Ther 2017 ;11:2087-2097
4145	Žurnāls	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4176	Žurnāls	Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M, Burgmann H, Reznicek G. Compatibility of linezolid with commercial peritoneal dialysis solutions Am J Health-Syst Pharm 2018 ;75:1467-1477
4254	Žurnāls	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Žurnāls	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4434	Žurnāls	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4461	Žurnāls	Tomczak S, Stawny M, Dettlaff K, Kieliszek, M, Słominska D, Jelinska A. Physicochemical Compatibility and Stability of Linezolid with Parenteral Nutrition. Molecules 2019 24, 1242.
4528	Žurnāls	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Žurnāls	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Žurnāls	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Žurnāls	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Žurnāls	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	Žurnāls	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.

Mentions Légales